1492 Capital Management LLC acquired a new stake in Revance Therapeutics Inc (NASDAQ:RVNC) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 38,966 shares of the biopharmaceutical company’s stock, valued at approximately $1,393,000. Revance Therapeutics accounts for 1.1% of 1492 Capital Management LLC’s investment portfolio, making the stock its 29th largest position. 1492 Capital Management LLC owned 0.11% of Revance Therapeutics as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Revance Therapeutics in the third quarter valued at $144,000. Teacher Retirement System of Texas purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $255,000. Voya Investment Management LLC purchased a new stake in shares of Revance Therapeutics in the second quarter valued at $274,000. Quinn Opportunity Partners LLC purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $325,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Revance Therapeutics in the fourth quarter valued at $343,000. 95.14% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently commented on RVNC shares. Mizuho started coverage on Revance Therapeutics in a research report on Thursday, November 16th. They issued a “buy” rating and a $37.00 price objective for the company. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. Barclays initiated coverage on Revance Therapeutics in a report on Monday, November 27th. They issued an “overweight” rating and a $31.00 target price on the stock. ValuEngine cut Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Finally, Piper Jaffray Companies lifted their target price on Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $45.45.
Revance Therapeutics Inc (NASDAQ RVNC) opened at $33.70 on Tuesday. Revance Therapeutics Inc has a fifty-two week low of $18.00 and a fifty-two week high of $37.45. The firm has a market capitalization of $1,201.43, a price-to-earnings ratio of -8.45 and a beta of 1.36.
Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the previous year, the business posted ($0.95) EPS. Revance Therapeutics’s revenue was down 50.7% compared to the same quarter last year. research analysts expect that Revance Therapeutics Inc will post -3.64 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/1492-capital-management-llc-takes-1-39-million-position-in-revance-therapeutics-inc-rvnc.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.